Compare Eni SpA (E) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Incyte Corporation — how do they compare? Eni SpA trades at $56.11 (market cap $79.81B), while Incyte Corporation trades at $113.2 (market cap $22.85B). The key difference: Eni SpA is far larger — about 3.5× Incyte Corporation's market cap, and Eni SpA pays a 4.39% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Incyte Corporation for 33 Days on average.
| E | INCY | |
|---|---|---|
Market Cap | $79.81B | $22.85B |
Volume | 365,912 | 1,927,029 |
Sector | Energy | Health |
52-Week High | $57.61 | $129.93 |
52-Week Low | $34.03 | $83.80 |
Typical Hold Time | 53 Days | 33 Days |
Enterprise Value | $104.34B | $18.35B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $56.09, up 3.95% on the day, with mixed technical signals showing bearish moving averages but oversold short-term RSI. Fundamentally, the company shows attractive valuation metrics with P/E of 12.87 and EV/EBITDA of 4.18, though revenue has declined from $132.5B in 2022 to $82.2B in 2025. Recent news highlights strategic initiatives including humanoid robotics partnerships and fuel discount programs.
The stock presents value opportunity with strong cash flow generation and dividend yield, but faces headwinds from declining revenue trends and recent earnings misses. Analyst consensus leans cautious with 62% hold ratings, suggesting patience required for operational turnaround despite attractive valuation multiples.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
